Physician profile
Michael Valitutto
NPI 1326074378
$1,751,968.39
in general payments reported to CMS, 2019-2025
37 companies · $309K in 2025
The $309K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266K · 2020: $198K · 2021: $262K · 2022: $275K · 2023: $188K · 2024: $253K · 2025: $309K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $529K · Travel and Lodging: $128K · Honoraria: $27K · Food and Beverage: $26K · Consulting Fee: $22K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $19K · Education: $139 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $529,338.54 |
| Travel and Lodging | $127,603.60 |
| Honoraria | $26,988.00 |
| Food and Beverage | $25,734.36 |
| Consulting Fee | $22,032.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $18,779.25 |
| Education | $139.36 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $589,191.04 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $359,683.99 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Corcept Therapeutics | $232,769.54 | 2019-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $182,405.05 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $98,754.57 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70,703.65 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Insulet Corporation | $56,240.68 | 2019-2025 | Omnipod, Omnipod |
| Amgen INC. | $28,238.78 | 2019-2025 | Tepezza, Repatha |
| Sanofi-Aventis U.S. LLC | $23,435.34 | 2019-2025 | |
| Abbott Laboratories | $23,069.34 | 2020-2025 | Freestyle Libre 3 |
| Cequr Corporation | $20,093.10 | 2024-2025 | Cequr Simplicity |
| Horizon Therapeutics Plc | $12,745.12 | 2020-2023 | Tepezza |
| Glaxosmithkline, LLC. | $12,350.00 | 2024 | |
| Abbvie INC. | $10,472.16 | 2019-2022 | |
| Dexcom, INC. | $8,795.15 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Valitutto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.